Table 1. Characteristics of clinical trials for neglected tropical diseases.
| Condition | Adult Trials, n | Pediatric Trials, n | Characteristics of Pediatric Trials | |||||
|---|---|---|---|---|---|---|---|---|
| Drug Trials, n (%) |
Vaccine Trials, n (%) |
Randomized Trials, n (%) | Industry Funded, n (%) | Enrollment, median | Trial Duration in Years, mean* | |||
| Dengue and chikungunya | 42 | 21 | 5 (23.8) | 16 (76.2) | 20 (95.2) | 17 (80.9) | 504 | 3.3 |
| Schistosomiasis | 6 | 14 | 12 (85.7.0) | 2 (14.3) | 12 (85.7) | 2 (14.3) | 490 | 1.6 |
| Soil Transmitted Helminthiases | 12 | 9 | 9 (100.0) | 0 | 7 (77.8) | 2 (22.2) | 350 | 1.3 |
| Leishmaniasis | 87 | 5 | 5 (100.0) | 0 | 3 (60.0) | 0 | 80 | 2.9 |
| Rabies | 33 | 4 | 0 | 4 (100.0) | 2 (50.0) | 3 (75.0) | 246 | 0.8 |
| Chagas | 19 | 2 | 2 (100.0) | 0 | 1 (50.0) | 1 (50.0) | 205 | 2.0 |
| Scabies and Other Ectoparasites | 18 | 2 | 1 (50.0) | 1 (50.0) | 1 (50.0) | 0 | 266 | 1.4 |
| Trachoma | 11 | 2 | 2 (100.0) | 0 | 2 (100.0) | 0 | 1,657 | 6.1 |
| Yaws | 3 | 2 | 2 (100.0) | 0 | 2 (100.0) | 0 | 419 | 1.3 |
| Human African Trypanosomiasis | 5 | 1 | 1 (100.0) | 0 | 0 | 0 | 125 | 3.2 |
| Taeniasis/Cysticercosis | 5 | 1 | 1 (100.0) | 0 | 1 (100.0) | 0 | 97 | 1.6 |
| Dracunculiasis | 0 | 0 | - | - | - | - | - | - |
| Echinococcosis | 1 | 0 | - | - | - | - | - | - |
| Foodborne Trematodiases | 1 | 0 | - | - | - | - | - | - |
| Leprosy | 18 | 0 | - | - | - | - | - | - |
| Lymphatic filariasis | 16 | 0 | - | - | - | - | - | - |
| Mycetoma, chromoblastomycosis, and other deep mycoses | 6 | 0 | - | - | - | - | - | - |
| Onchocerciasis | 8 | 0 | - | - | - | - | - | - |
| Buruli Ulcer | 3 | 0 | - | - | - | - | - | - |
| Snake Bite Envenomation | 12 | 0 | - | - | - | - | - | - |
| Total | 306 | 63 | 42 (66.6) | 21 (33.3) | 52 (85.3) | 25 (39.7) | 315 | 2.3 |
*Completion dates for the calculation of trial duration were missing for 4 trials on dengue, 2 trials on schistosomiasis, and 1 trial each on leishmaniasis, rabies, trachoma, and soil transmitted helminthiases.